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Abstract 54 
 55 
The aim of this study was to examine the roles of L-fucose and the glycosaminoglycans (GAGs) keratan 56 
sulphate (KS) and chondroitin sulphate/dermatan sulphate (CS/DS) with selected functional molecules 57 
in neural tissues. Cell surface glycans and GAGs have evolved over millions of years to become cellular 58 
mediators which regulate fundamental aspects of cellular survival. The glycocalyx, which surrounds all 59 
cells, actuates responses to growth factors, cytokines and morphogens at the cellular boundary 60 
silencing or activating downstream signalling pathways and gene expression. In this review we have 61 
focussed on interactions mediated by L-fucose, KS and CS/DS in the central and peripheral nervous 62 
systems. Fucose makes critical contributions in the area of molecular recognition and information 63 
transfer in the blood group substances, cytotoxic immunoglobulins, cell-fate mediated Notch-1 64 
interactions, regulation of selectin mediated neutrophil extravasation in innate immunity and CD-34 65 
mediated new blood vessel development and the targeting of neuroprogenitor cells to damaged neural 66 
tissue. Fucosylated glycoproteins regulate delivery of synaptic neurotransmitters and neural function. 67 
Neural KS-proteoglycans were examined in terms of cellular regulation and their interactive properties 68 
with neuroregulatory molecules. The paradoxical properties of CS/DS isomers decorating matrix and 69 
transmembrane proteoglycans and the positive and negative regulatory cues they provide to neurons 70 
is also discussed.  71 
 72 
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Abbreviations 96 
 97 
AD   Alzheimer’s disease 98 
ADAM   a disintegrin and metalloproteinase domain  99 
ADAM-TS  a disintegrin and metalloproteinase domain with thrombospondin motifs 100 
ADCC   antibody dependent cellular cytotoxicity 101 
AGE   advanced glycation end product  102 
Akt   protein-kinase B  103 
ALS   amyotrophic lateral sclerosis 104 
APP   amyloid precursor protein 105 
ATP   adenosine triphosphate 106 
BDNF   brain derived neurotrophic factor 107 
β3GlcNAcT  β1,3-N-acetylglucosaminyltransferase 108 
CS   chondroitin sulphate 109 
CSPG   chondroitin sulphate proteoglycan 110 
CSL    an acronym for CBF-1/RBPJ (recombining binding protein   111 
   suppressor of hairless) 112 
CNS   central nervous system 113 
DCC   a receptor named Deleted in Colorectal Cancer  114 
DRG   dorsal root ganglion 115 
DS   dermatan sulphate 116 
DS   dermatan sulphate proteoglycan 117 
ECM   extracellular matrix 118 
EGF   epidermal growth factor 119 
EGFR   epidermal growth factor receptor 120 
ER   endoplasmic reticulum 121 
ERK   extracellular signal-regulated kinase 122 
FGF   fibroblast growth factor 123 
FGFR   fibroblast growth factor receptor 124 
FcγRIIIA   activating Fc receptor specific for IgG Fc region expressed by   125 
   HNK cells and macrophages 126 
FUT   fucosyl transferase 127 
GAG   glycosaminoglycan 128 
GlcNAc6ST   n-acetylglucosamine-6-O-sulfotransferase 129 
GSK   glycogen synthase kinase  130 
GTP   guanosine triphosphate 131 
HMBG-1   high-mobility group box-1 protein  132 
HNK   human natural killer 133 
HS   heparan sulphate 134 
HA   hyaluronan 135 
IGD   interglobular domain 136 
IGFBP2   insulin-like growth factor binding protein-2 137 
IgG   immunoglobulin G 138 
KS   keratan sulphate 139 
KSPG   keratan sulphate proteoglycan 140 
KSGal6ST   keratan sulfate galactose 6-O-sulfotransferase 141 
LAD II    leukocyte adhesion deficiency II 142 
LAR   leukocyte common antigen related 143 
LC-MS   liquid chromatography-mass spectroscopy 144 
LRR   leucine rich repeat 145 
MAb   monoclonal antibody 146 
MAPK   mitogen-activated protein kinase 147 
NCAM   neural cell adhesion molecule 148 
NG2   neural/glial antigen 2 149 
NMR   nuclear magnetic resonance 150 
2D MRS   two dimensional magnetic resonance spectroscopy 151 
NG2   neural/glial antigen-2 (CSPG-4)  152 
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NGF   neural growth factor   153 
PKA   cAMP dependent protein kinase 154 
POFUT   GDP-fucose protein O-fucosyltransferase 1 155 
POFUT   protein - fucosyl transferase  156 
PG   proteoglycan 157 
PNS   peripheral nervous system 158 
PSGL-1   selectin-P ligand (CD162) 159 
PTP   protein tyrosine phosphatase σ  160 
RAGE   receptor for advanced glycation end products 161 
RPTP-σ   receptor-like protein tyrosine phosphatase-σ 162 
SCI   spinal cord injury 163 
SHH   sonic hedge hog 164 
sLeX   sialyl Lewis-X antigen 165 
Trk B   tyrosine receptor kinase B 166 
TGF-β   transforming growth factor-β 167 
TNF-α   tumour necrosis factor-α 168 
TSRs   thrombospondin repeats 169 
SYN   synapsin 170 
RPTP-   receptor protein tyrosine phosphatase-zeta 171 
Wnt   this is a condensation of terms describing the Winged and Int transcription 172 
   factor morphogens 173 
  174 
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1. Introduction 175 
1.1 Aim 176 
 This study reviews the roles of selected glycans and glycosaminoglycans (GAGs) which 177 
decorate neural glycoproteins and proteoglycans (PGs) and examines how they contribute to neuronal 178 
function and repair processes.  Due to the complexity of the large number of neural effector molecules 179 
and their broad interplay with receptors, ion channels, synaptic and axonal structures in health and 180 
disease it has not been possible for this review to provide a comprehensive coverage of all of these 181 
aspects.  Rather, key interactive molecules have been focussed on and novel aspects of the functional 182 
roles of glycans such as L-fucose and GAGs such as keratan sulphate (KS) and chondroitin/dermatan 183 
sulphate (CS/DS).  The role of heparan sulphate (HS) in neuronal development and function and also 184 
pathogenesis (e.g in neurodegenerative conditions  such as Alzheimer’s disease (AD) is a significant 185 
area of glycobiology under intense scientific scrutiny and, as such, is outside the scope of the current 186 
review. For this, the reader is referred to a number of recent studies [1-6]. 187 
 188 
 189 
1.2 Analysis of glycan and glycosaminoglycan complexity 190 
 While the structural complexity of glycan structures is a daunting subject to investigate [7-10] 191 
powerful analytics have been developed to assist in these investigations. These new methodologies 192 
include ion-mobility mass spectrometry [11, 12], application of synchtrotron radiation for glycan 193 
structural analysis [13], application of high throughput automated N-glycopeptide glycoproteomic 194 
identification systems and orbitrap mass spectrometry [14-16], integrated systems glycobiology 195 
methodology incorporating glycogenomics, glycoproteomics and glycomics [17], fully automated chip-196 
electrospray mass spectrometric analysis for the determination of CS/DS fine structure[18].  GAG 197 
microarrays for the analysis of GAG-protein interactions [19-21] have also been applied to profiling the 198 
sulphation patterns of GAGs to determine growth factor interactive sequences [22, 23] and have also 199 
identified CS-E tetrasaccharides motifs which act as TNF antagonists [24].  Development of clickECM 200 
cell-derived azide functionalised extracellular matrices (ECMs) [25], photoactivatable and 201 
chemoenzymatic glycan labelling tools [26-28], non-invasive two dimensional nuclear magnetic 202 
resonance spectroscopy [29], glycoengineering of monoclonal antibodies (MAbs) with improved 203 
carbohydrate-protein interactive properties and immune cell targeting capability has improved their 204 
efficacy in anti-cancer therapeutics [30].  Multimodal glycosylated conductive polymer biointerfaces 205 
suitable for the evaluation of carbohydrate-protein interactions [31] and nanoscale biomatrices for 206 
studies on glycocalyx interactions [32] have been developed.  Such approaches have been applied to 207 
the translation of the  'Sugar Code' into immune and vascular signaling programs with potential 208 
therapeutic application [33], such an approach may also provide a better comprehension of the 209 
complexities of altered glycodynamics in brain conditions such as Alzheimer’s disease, Parkinson’s 210 
disease, schizophrenia, epilepsy and neural conditions characterised by altered cognitive learning [34]. 211 
 212 
 Analysis of the structural complexity of glycans has been considerably aided with the 213 
development of software packages which simplify unambiguous representation of glycans and their 214 
structural forms.  These include GlycanBuilder [35], KCam[36], GlycResoft, a software package for 215 
automated recognition of glycans from liquid chromatography-mass spectrometry (LC-MS) data[37], 216 
KEGG Carbohydrate matcher (http://www.genome.jp/ligand/kcam/), SWEET-DB, annotated 217 
carbohydrate data collections[38], DrawRINGS, 2D Glycan structure Drawing Tool 218 
(http://rings.t.soka.ac.jp/java/DrawRings.html), LINUCS: linear notation for unique description of 219 
carbohydrate sequences[39], GLYDE (http://glycomics.ccrc.uga.edu/GLYDE-CT/) [40], EUROCarbDB 220 
tools to normalise and convert glycan structures: Glycan builder 221 
(http://www.eurocarbdb.org/applications/structure-tools) and  analysis of MS spectra : 222 
GlycoWorkbench (http://www.eurocarbdb.org/applications/structure-ms-tools). PROCARB is a 223 
database of known and modelled carbohydrate binding protein structures with sequence based 224 
prediction tools[41]. Establishment of the Consortium for Functional Glycomics (CFG, 225 
http://functionalglycomics.org/static/consortium/consortium.html) in 2001 has aided glycan research 226 
through the extensive, highly informative reference material readily available on their web-site.  227 
Informatics tools are also available for the analysis of GAG structure[42] and conformation [43] and for 228 
the determination of interactive GAG sequences [44-49].  Glycomics databases such as EuroCarbDB 229 
(http://www.ebi.ac.uk/eurocarb/home.action) and The Functional Glycomics Gateway 230 
(http://www.functionalglycomics.org/), Databases of Conformations and NMR Structures of Glycan 231 
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Determinants [50] and software for the structural determination of GAGs by mass spectrometry [51], 232 
and for automated comparison of low molecular weight heparins from LC/MS data [52] have also 233 
been developed [51].  Nuclear magnetic resonance (NMR) spectroscopy has also been applied to the 234 
structural analysis of sulphated fucose-CS polymers [53].  Furthermore, novel high sensitivity, low 235 
toxicity alkynyl-fucose substrates have been developed for the visualisation of fucose incorporation 236 
into glycopolymers, these alkynyl-fucose substrates  are incorporated into N-glycans by a wide range of 237 
fucosyl transferases[54] enabling their visualisation in cells using biotin-steptavidin Alexa-488 238 
histochemistry and they may be extracted, separated by SDS PAGE and identified by Western blotting 239 
[53]. The complexity of glycans surpasses by several magnitudes that of the other major life 240 
biomolecules, proteins, lipids and nucleic acids [9, 10, 21, 55, 56] and their analysis has lagged behind 241 
due to this complexity however with the improvement in glycan analysis now possible with the 242 
methodology outlined above this gap is steadily closing.   243 
 244 
 Glycan biodiversity occurred over at least 500 million years of vertebrate and invertebrate 245 
evolution and an even longer evolutionary period in bacteria leading to their evolution as mediators of 246 
cellular interaction. Glycans occur in the glycocalyx of all cells and they are the first point of contact 247 
between that cell and other cells, with that cell and the extracellular matrix or with any invading 248 
organism. Thus there were heightened evolutionary pressures on these front-line glycans to develop 249 
recognition and effector roles, with this major positive selection stimulus glycans diversified into their 250 
present day level of complexity.  The glyco-code could therefore be considered a biodiverse IT 251 
database which nature has developed over a very significant evolutionary period [57]. Thus many 252 
structural permutations were explored and those glycan structures that have persisted to the present 253 
day are ones which offer interactive capability with effector molecules in essential physiological 254 
processes providing improved survival traits. Deciphering this glyco-code using the sophisticated 255 
glycobiological methodology now available is an important research objective and may uncover 256 
invaluable insights as to how glycans regulate cells and be of application in repair biology. 257 
 258 
2. The complexity of neural tissues 259 
2.1 Cell types in the central and peripheral nervous system. 260 
 Neurons and glial cells have a common neuro-epithelial origin in the embryonic nervous 261 
system and thus share many structural and molecular characteristics [58, 59]. Neurons and glial cells 262 
display unique properties which distinguish these cell types from others.  Approximately 10% of all cells 263 
in the tissues of the central and peripheral nervous systems (CNS/PNS) are neurons.  Accessory cell 264 
types also include astrocytes, radial glia, oligodendrocytes, ependymal cells, microglia and 265 
microvascular endothelial cells while neural/glial antigen 2 (NG2) positive glia are also considered to be 266 
a distinct cell type.  Microglia are fundamentally distinct from other brain cell types, being derived from 267 
primitive peripheral myeloid progenitors during embryogenesis. Microglia are the resident phagocytic 268 
cells of the brain, taking part in immune-mediated defense processes which clear damaged cell debris 269 
while other glial cells have roles in the nutrition of the neuron and maintenance of axonal structures 270 
[58-61].  271 
 272 
 The CNS/PNS has an extensive blood supply which services its considerable metabolic 273 
demands. Like most cells in the human body, glucose, is also the primary energy source for neurons.  The 274 
brain is the most energy-demanding organ in the human body and while it may only constitute ~2% of the 275 
total mass of the human body it uses 20% of the bodies total energy production [62]. Glucose metabolism 276 
is the physiological fuel for brain function and is also required for the generation of ATP and the precursor 277 
compounds required in the synthesis of neurotransmitters needed for cell signalling. Brain functions such 278 
as thinking, memory, and cognitive learning are intricately interlinked to efficient utilisation of glucose in 279 
energy production [63].  However, too much glucose as occurs in type I and II diabetes can also be 280 
detrimental to brain function.  Type 2 diabetes accelerates brain aging and accelerates functional decline 281 
in dementia resulting in significant age dependent cognitive changes in brain function.  282 
 283 
While glycans are of particular importance in the provision of the metabolic demands of the CNS/PNS, 284 
they also have significant recognition roles in neuronal regulation. Neurons are terminal post-mitotic 285 
cells with the ability to communicate precisely and rapidly with other cells in the neural system 286 
through long cellular extensions (dendrites) that extend to distant sites in the body. Two features 287 
equip neurons with this interactive capability: (i) Neurons have receptive dendrites in the cell body and 288 
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a transmitting axon at the other end, this arrangement is the structural basis for unidirectional 289 
neuronal signaling, (ii) Neurons are electrically and chemically excitable cell types. The neuron cell 290 
plasma membrane contains specialized ion channels and receptor proteins that facilitate the regulated 291 
flow of specific inorganic ions in and out of the neuron, thereby redistributing charge and creating 292 
intracellular electrical micro-currents that alter the voltage across membranes. Such charge changes 293 
can produce a wave of depolarization in the form of action potentials along the axon and this is the 294 
usual way a signal and neurotransmitter molecules are transmitted from one neuron to another [64].  295 
A waxy myelinated sheath surrounding the axon ensures that high conduction velocities are 296 
maintained in neurons to optimise their excitatory transmitter properties (Fig 1). Neuro-transmitters 297 
are synthesised in the Golgi/endoplasmic reticulum (ER) of the neuronal cell body (soma) and 298 
transported by a microtubular system towards the pre-synaptic membrane where they are stored in 299 
synaptic vesicles for later co-ordinated delivery into the synaptic gap for transportation to a 300 
communicating neuron.  Neurons do not use their microtubular assemblies for cell division like other 301 
cells, but they use these as internal scaffolding elements for the elongation of axons and dendritic 302 
processes. Microtubules act as compression-bearing struts that contribute to the shape of the neuron 303 
and also act as directional conduits for the transport of neurotransmitters and organelles from the cell 304 
body to the synaptic terminals (Fig 2). Synaptic vesicle membranes contain the fucosylated 305 
glycoprotein synaptophysin, which forms pore-like assemblies that provide portals for the entry of 306 
Ca2+ ions in and out of these structures.  Synapsin is another major fucosylated vesicle associated 307 
glycoprotein which interacts with the cytoskeleton tethering synaptic vesicles and co-ordinating their 308 
transport to the synaptic gap for eventual synchronised neurotransmitter transmission across the 309 
synaptic gap to communicating nerves in the neural network.  310 
 311 
 While glial cells are a less excitable cell type than neurons, their membranes nevertheless also 312 
contain transporter proteins that facilitate the uptake of ions as well as proteins that remove 313 
neurotransmitter molecules from the extracellular space.  Thus glial cells act as accessory support cell 314 
types to regulate neuronal function and also have roles in the nutrition of neurons and assembly of the 315 
myelin sheath. In addition, they undertake running repair processes to ensure the maintenance of 316 
neuronal structural integrity (Fig 2). Sophisticated regulatory systems are in place to facilitate neuron-317 
glial cell communication [65-69].  Phosphorylation, ubiquitination, and glycosylation of proteins 318 
facilitate weak interactions with multivalent adaptor proteins resulting in the formation of membrane-319 
associated and soluble complexes that mediate information transfer between cells. These systems are 320 
dynamic and complex and display remarkable specificity to control signaling pathways and effective 321 
communication between neurons and glial cells. 322 
 It is estimated that there are over 100 distinct types of neurons in humans. These display 323 
molecular and cytological bio-diversity displaying different cell body shapes and arrangements of 324 
dendritic processes in variable depths of the cerebral cortex. All neurons inherit the same complement 325 
of genetic information during development, however each neuron expresses a restricted set of genes 326 
in-situ and they produce a restricted range of enzymes, structural, membrane and secretory proteins 327 
specifically designed to service their precise environmental needs.  While neurons have lost the ability 328 
to replicate they, nevertheless, are capable of re-growth after injury provided the resident inhibitory 329 
cues are circumvented and they receive appropriate stimulatory cues to promote neuritogenesis.  330 
Glycan modified proteoglycans and glycoproteins have important roles to play in this area providing 331 
both stimulatory and inhibitory cues which regulate neural repair and regrowth. 332 
 Astrocytes communicate extensively with neurons, define the margins of functional areas of 333 
the brain including gliotic scars and also stabilise its internal environment.  The extracellular 334 
components the astrocytes lay down (e.g. abakan) form a barrier interfacing with the blood brain 335 
barrier to exclude components from entry into brain tissues or the glial scar [70]. Astrocytes provide 336 
nutrients to neurons and maintain the integrity of neuronal components replacing old and damaged 337 
tissue. Astrocytes modify neuronal signals by secreting glio-transmitters and generating waves of Ca2+ 338 
action potentials with regulatory properties.  Astrocytes also regulate blood flow through extensions 339 
which encircle blood vessels and mediate communication with the lining endothelial cells (Fig 2j).  340 
Oligodendrocytes assemble the myelin sheath around neurons. Astrocytes also attach to this encircling 341 
structure on the neuron which represents a direct line of communication between these two cell types. 342 
These astrocyte interconnections dilate and contract blood vessels and influence neuronal signaling in 343 
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a dynamic manner to regulate blood flow and neuronal action [71].  Thus the astrocyte is an important 344 
coordinative regulator of synaptic function and is believed to have important roles in cognitive learning 345 
and memory processes.  A single neuron may contain as many as 100,000 synapses and the neuron 346 
relies on astrocytes to help control synaptic function through elaborate bidirectional communication 347 
between the astrocyte and the neuron. Astrocytes are an underappreciated cell type in neuronal 348 
tissues. Astrocytes, like neurons also produce neurotransmitters, generate their own calcium based 349 
action potentials and have receptors and ion channels which facilitate constant astrocyte-neuronal 350 
communication [72] .  351 
 352 
 CD34 is an important fucosylated endothelial cell surface molecule containing glycan 353 
interactive structures which affect the homing of progenitor cells in microvessels [73, 74].  CD34+  354 
bone marrow haemopoietic stem cells are recruited to sites of brain trauma and differentiate into 355 
microglia which participate in neuronal repair processes. ALS, a complex multifactorial progressive 356 
degenerative disease with numerous intrinsic and extrinsic factors underlying its etiopathogenesis also 357 
displays degenerative vascular pathology underpinned by endothelial cell degeneration [75]. AS 358 
discussed more fully later in this review, L-Fucose is a component of many O-linked and N-linked 359 
glycan modifications in a number of glycoproteins with important functional roles in many 360 
physiological and pathophysiological neural processes[76]. O-Fucosylation occurs at consensus 361 
sequences on two small cysteine-rich domains in Epidermal growth factor-like (EGF) repeats and 362 
Thrombospondin Type 1 Repeats (TSRs) in glycoproteins such as Notch-1, CD-34 and thrombospondin-363 
1 [77]. Mouse Notch-1 contains three O-fucosylation sites in EGF repeats 1-5 and thrombospondin-1 364 
has three fucosylation sites in thrombospondin repeats 1-3 [78]. 6-Alkynyl fucose (6AF) is an L-fucose 365 
analogue (Fig 4j) which has been developed to facilitate labelling and tracking of these L-fucose motifs 366 
in physiological processes [79]. Over 100 proteins are predicted to be O-fucosylated on the basis of 367 
identified consensus EGF repeat sequences [80].  The Notch receptor family have more predicted O-368 
fucosylation sites than any other protein in the recorded databases [81] (Fig 5).  Many groups have 369 
shown that O-fucosylation is essential for Notch’s functional properties [80, 82-84]. O-fucose also has 370 
functional roles in agrin which enables this proteoglycan to cluster acetylcholine receptors in the NMJ 371 
[85].  The precise function of O-fucose in the vast majority of these proteins however is unknown.  372 
Thrombospondins produced by astrocytes have roles in the formation of synapses.  373 
 374 
 -fucose is a terminal or core monosaccharide on N-and O-linked glycan chains on many 375 
glycoproteins  (Fig 4d, Fig 5a-g).  It also occurs as a capping structure along with sialic acid on the KS-I 376 
and KS-II chains of PGs (Fig 4a-c) and in terminal sLeX motifs in glycoproteins (Fig 4f, Fig 5b, Fig 6f-h).  377 
KS is heavily substituted with fucose and sialic acid in ALS. The prominent terminal locations of L-fucose 378 
points to its role as a molecular recognition site for interacting proteins. Fucose occurs as a terminal 379 
sugar linked to a penultimate galactose residue in glycoconjugates or to core GalNAc residues in N-380 
glycans (Fig 5b,f).  Fucose can also be directly attached to serine or threonine residues by fucosyl 381 
transferases in O-linked glycans and can act as an acceptor molecule for the attachment of further 382 
saccharides to form small oligosaccharide side chains (Fig 4e). 383 
 384 
3. Functional roles of the glycosaminoglycan components of brain extracellular and cell associated 385 
proteoglycans in neuroregulation 386 
 387 
3.1 Neural proteoglycans 388 
  ECM proteoglycans (PGs) play important directive roles in the growth of axons and in the 389 
navigation, plasticity and regenerative properties of neurons.  PGs have paradoxical roles in neuronal 390 
growth and repair processes where they can both promote neuronal growth but in other settings can 391 
inhibit neural repair [86]. The sulphation positions and charge density of the GAG side chains of PGs 392 
can be sources of important signals to the neurons which either inhibit or promote neuronal repair 393 
[86]. Thus the CS-A and CS-C chains of lectican PGs such as aggrecan, versican, neurocan and brevican 394 
are sources of inhibitory signals and a barrier to neural outgrowth in perineural net formations (Fig 3) 395 
which surround areas of axonal damage in glial scar formations [87-90]. CS isomers of higher charge 396 
density such as the CS-D and CS-E motifs of phosphacan, bikunin and appican can actually promote 397 
neuronal repair processes. Thus, collectively, these CS isomers guide axonal growth and repair with 398 
remarkable specificity [91-94].  Another GAG present in some neural PGs is keratan sulphate (KS) and 399 
interesting interactive properties are now emerging for this GAG. 400 
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 401 
3.2 An Emerging Role for KS in the regulation of neuritogenesis 402 
 403 
 The sulphation status of GAGs is an important functional determinant conveying important 404 
molecular recognition and information transfer properties that control cellular behavior [57, 95-98]. 405 
GAG sulphation motifs on PGs interact with cytokines, growth factors, chemokines, morphogenetic 406 
proteins, and extracellular matrix components modulating signaling pathways which control diverse 407 
aspects of cellular behaviour such as proliferation, differentiation, migration and matrix synthesis. 408 
After the cornea, neural tissue is the next richest source of KS, however it is a relatively neglected GAG 409 
and relatively little is known of its functional properties [99].  When dordal root ganglion (DRG) 410 
neurons are cultured on a substratum of CS-PGs, neurite outgrowth is inhibited, correlating with the 411 
reduced neural repair evident in glial scar tissue where levels of CS-PGs are elevated [87, 100, 101].  412 
Treatment of DRG neuron cultures with chondroitinase ABC or keratanase results in a recovery of 413 
neurite outgrowth and these enzymatic treatments also promote neural repair processes in models of 414 
axonal damage [102-104]. KS and CS can both be sources of inhibitory signals in neuritogenesis. Three 415 
molecular forms of KS have been identified.  KS-I and KS-II are substituted with L-fucose which has 416 
recognition roles in N- and 0-linked glycans [99], KS-III is also found in the brain [105]. O-fucosylation of 417 
the KS chains attached to aggrecan vary along its core protein (Fig 4).  The KS-II chains in the KS-rich 418 
region contain capping fucose and sialic acid residues but this varies in tissues.  These capping 419 
structures occur in aggrecan isolated from intervertebral disc and articular cartilage but not in 420 
aggrecan isolated from non-weight bearing cartilaginous tissues such as the trachea or nasal cartilage.  421 
KS chains interspersed within the CS-2 region of aggrecan are more heavily fucosylated than the KS 422 
chains in the KS rich region or the small KS chains found in the G1 and G2 or interglobular domains.  423 
These CS-2 KS chains are detected by MAb 3D12H7 [106].  It is not known to what extent brain 424 
aggrecan displays such KS modifications, KS chains are however heavily substituted with L-fucose and 425 
sialic acid in amyotropic lateral sclerosis (ALS) [99].  The functional significance of these L-fucose and 426 
sialic acid substitution patterns on KS has not been determined but it is conceivable that they may 427 
modify or sterically impede the interactive properties of KS with neuromodulatory molecules. 428 
 429 
 Specific KS-PGs (e.g. phosphacan) in the CNS/PNS contain highly charged KS chains and display 430 
anti-adhesive properties inhibiting the attachment of neural cells to tenascin-C and laminin and this 431 
promotes neuronal outgrowth and axonal repair processes [107, 108]. Other brain KS-PGs (e.g. abakan, 432 
PG1000, SV2, claustrin) also contain 5-D-4 positive KS chains which confer interactive properties in 433 
neurotransmission, and synaptogenesis [109]. Localization of low and high sulphation phosphacan KS 434 
motifs in the Zebra song finch brain are correlated with neural development and cognitive song-435 
learning [110]. Low sulphation KS is diffusely distributed throughout the brain while highly sulphated 436 
KS is specifically expressed in the song nuclei centres. GlcNAc-6-O-sulphotranferase (GlcNAc6ST), the 437 
enzyme responsible for the biosynthesis of highly sulphated KS is also exclusively associated with the 438 
song nuclei. Highly sulphated phosphacan localized to the perisynaptic spaces and dendrites but not 439 
the presynapse of the mouse visual cortex has roles in synaptic plasticity [111]. GlcNAc6ST knockout 440 
mice express one half of the level of KS of wild type mice.  Highly sulphated KS-phosphacan generates 441 
T-type Ca2+ channel mediated long-term potentiation of non-deprived eye responses after 442 
mononuclear deprivation. E 3GlcNAcT-7 and GlcNAc6ST-1, TGF- and FGF-2 in adult 443 
mice is elevated in gliotic scars [112]. Fibroblast growth factor 2 (FGF-2) elevates TGF-1 production by 444 
astrocytes and KS expression in gliotic scars which inhibit neural repair.  GlcNAc6ST knockout mice 445 
display reduced KS expression and enhanced neural regeneration after brain injury [101]. KS-PGs 446 
focally upregulated in spinal cord injuries are laid down by reactive microglia, macrophages and 447 
oligodendrocyte precursor cells but not by astrocytes [113]. Astrocytes do however produce the KS-PG 448 
abakan following injury which defines functional areas and the margins of gliotic scars in the cerebral 449 
cortex [114].  Abakan is also  associated with malignant astrocytic  tumours [115] and glioblastoma 450 
[116].  Furthermore, highly sulphated KS levels however are severely reduced in AD with levels reduced 451 
to less than 50% of control tissue levels [117].  452 
 453 
 KS interactions with cell stimulatory molecules regulate tissue homeostasis. KS chains bind 454 
insulin-like growth factor binding protein-2 (IGFBP2) [118], Sonic Hedgehog (SHH), FGF1 and FGF2 455 
[119]. KS is a component of neural matrix and cell membrane PGs . KS-I interactions involving highly 456 
sulphated KS detected using MAb 5-D-4 have been demonstrated in a microarray of 8268 proteins and 457 
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custom array of 85 extracellular nerve growth factor protein epitopes [120].  Two hundred and 458 
seventeen of the 8268 microarray proteins interacted with KS including 75 kinases, several membrane 459 
and secreted proteins, cytoskeletal proteins and a number of nerve function proteins.  Surface plasmon 460 
resonance confirmed these interactions and allowed the determination of binding their constants. Of 461 
the 85 selected ECM nerve-related epitopes, KS bound 40 of these.  This included Slit, two Robo’s, nine 462 
ephrin receptors, eight ephrins, eight semaphorins, and two nerve growth factor receptors. The Slit-463 
Robo cell-signaling pathway is central to axonal guidance, angiogenesis and neurogenesis during spinal 464 
development.  The slit receptors contain variable numbers of LRR motifs and 7-9 EGF repeat domains 465 
which have protein interactive properties. KS interactions in the Robo-Slit cell signaling pathway 466 
produces downstream activation of Rho GTPases, actin depolymerisation and cytoskeletal re-467 
organisation. Direct cell-cell interactions between Ephrins and Ephrin protein-tyrosine kinase receptors 468 
also regulate a range of important intracellular signaling pathways during development, that control 469 
cell migration and are involved in axonal growth cone guidance. The semaphorins, which, exist as both 470 
secreted and membrane bound forms, are also involved in axonal growth cone guidance and provide 471 
short-range inhibitory signals through interactions with plexin and neuropilin receptors which regulate 472 
Rho family GTPases (Fig 8f, g).  Such interactions are critical to neural development and neural repair.  473 
As seen in Figure 4, substitution of KS-I and II with L-fucose may modulate their interactive properties 474 
with the aforementioned receptors.  L-Fucose has demonstrated roles in molecular recognition and 475 
receptor-ligand interactions involving Notch, selectin-P ligand (PSGL-1) and CD-34 [121-126].   476 
 477 
 KS coexists alongside CS chains in brain aggrecan [89, 127] and phosphacan [103, 107, 108, 478 
128, 129]. Neurite outgrowth of DRG neurons is inhibited when they are plated on to CS-PGs, and this 479 
inhibitory effect is removed by either chondroitinase ABC or keratanase treatment [102, 104]. 480 
Keratanase treatment promotes functional recovery of spinal cord injury [103].  Developmental 481 
changes in KS sulphation patterns are associated with alterations in plasticity and cognitive learning 482 
and functional recovery of neural tissues. GlcNAc6ST-1 knock out mice display no gross developmental 483 
phenotype, but show changes in the induction of glial scar formation [101], and better axonal growth 484 
after both cortical stab wounds and spinal cord injuries [130]. These studies emphasize the importance 485 
of highly charged KS chains identified by the KS antibody 5-D-4 in nerve repair processes. The 5-D-4 486 
MAb recognizes KS structures containing 6-sulphated Gal and GlcNAc residues. GlcNAc6ST1 and 487 
KSGal6ST both contribute to the generation of the 5-D-4 epitope and are essential for 6-sulphation of 488 
Gal within KS in the developing and adult brain and induced after injury [131] and in early postnatal 489 
brain development.  5-D-4 reactivity is abolished in the KSGal6ST knockout mouse brain.  The early 490 
phases of ALS are accelerated in GlcNAc6ST-1(-/-) mice where CNS KS is also ablated [132].  KS 491 
produced by M2 microglia suppress the early phases of ALS, microglia produce KS heavily modified 492 
with fucose and sialic acid. GlcNAc6ST1(-/-) mice display a complete absence of microglial KS but 493 
increased phagocytosis of amyloid  protein and reduced levels of cerebral amyloid deposition [133].  494 
Inhibition of KS biosynthesis by targeting GlcNAc6ST1 thus represents a therapeutic target in AD. 495 
Functional roles for KS have been suggested in spinal cord development in GlcNAc6ST1 knockout mice 496 
where KS binds to Shh and acts as a morphogen regulating murine embryonic spinal development 497 
[134]. KS interactions in late phase Shh signaling acts as a morphogenetic switch regulating the 498 
generation of oligodendrocyte progenitor cells from motor neurons [134].  The KS-PG, phosphacan also 499 
acts as a developmental molecular switch which regulates neuronal development.  KS chains inhibit 500 
neuronal attachment but promote outgrowth activity, an effect reversible by keratanase treatment 501 
[135]. 502 
 503 
Other lines of evidence demonstrate key roles for KS in development and repair/remodeling in other 504 
tissues. For example, KS may be chondroprotective in inflammatory arthritis models [136]. Murine 505 
aggrecan has a truncated core protein devoid of a KS rich region thus KS levels are low in murine knee 506 
joints.  Intraperitoneal administration of KS ameliorated IL-1 induced GAG release and protected 507 
cartilage from arthritic changes in GlcNAc6ST1 (-/-) mice.  Furthermore, GlcNAc6ST1 activity is 508 
significantly reduced in macular corneal dystrophy resulting in the occurrence of low- or non-sulfated 509 
KS and corneal opacity [137].   510 
 511 
3.3 CS/DS and their cell and matrix regulatory roles in neural tissues 512 
CS is the most abundant GAG in the human body and is O-sulphated at the 2, 4 and C6 positions [55].  513 
GlcA may also be epimerised to L-IdoA in the related GAG, DS, leading to structural diversity in CS/DS 514 
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with over one thousand different pentasaccharide combinations possible [55]. The large number of 515 
structural permutations possible with CS/DS facilitates interactions with a diverse repertoire of 516 
cytokines, chemokines, morphogens and growth factors with regulatory properties in tissue 517 
development and ECM remodelling [55, 138-142].  CS also occurs as a number of isoforms including 518 
the high charge density CS-D and CS-E and lesser charged CS-A, CS-B and CS-C [98]. CS-D and CS-E are 519 
enriched in the brain transmembrane PGs phosphacan, syndecan-1, syndecan-4, NG2 520 
proteoglycan/CSPG4, neuroglycan-C/CSPG7, and ECM PGs appican (-APP) and bikunin [143-145]. CS-521 
A, B, C are abundant in the brain hyalectan proteoglycan family consisting of brevican, neurocan, 522 
versican and aggrecan. The CS-D and CS-E motifs embedded within the CS-A side chains of -APP, 523 
bikunin and phosphacan convey neuroregulatory properties [108, 145]. While CS-D and CS-E can 524 
promote neural repair the same cannot be said of the CS-A, B, C side-chains of neural net PGs layed 525 
down in the gliotic scar. Perineural nets [146] have been immunolocalised in rat brain tissues using the 526 
MAb 1-B-5 to a non-sulphated aggrecan stub epitope generated by chondroitinase ABC.  1-B-5 527 
reactivity is displayed in extensive extracellular distributions encompassing a large group of neurons 528 
(Fig 3 a, b) as well as pericellularly surrounding single or small numbers of neurons (Fig 3c, d) [147].  529 
Formation of glial scars, seals the injury but also creates a barrier to axonal regrowth. The scar centre is 530 
highly inflammatory and populated by NG2+ glia, astrocytes seal the border of the scar but in so doing 531 
entrap axons attempting to regrow within the scar, thus activated astrocytes and ECM components laid 532 
down in the scar contribute to regenerative failure[148]. The NG2 positive glia are a progenitor cell 533 
type for oligodendrocytes which participate in neural remodelling and repair processes whereas 534 
astrocytes define the boundary of the gliotic scar and do not participate in its repair. PGs in neural 535 
tissues thus have paradoxical modes of action, CS-PGs, of the lectican family hinder axonal regrowth 536 
while the transmembrane CS-PG (NG2/CSPG4) and phosphacan, upon shedding from the cell by ADAM 537 
10 (a disintegrin and metalloproteinase containing protein 10), promote axonal re-growth and 538 
production of synaptic adhesion molecules, promoting synaptic signaling, plasticity and functional 539 
recovery. The positive contribution of CSPG4 to neural repair processes is confirmed from knockout 540 
studies of NG2/CSPG4 mice which display aggravated tissue loss, inflammation and neurologic deficits 541 
after traumatic brain injury.  Progranulin, a functional ligand of Notch and Eph2a acts in concert with 542 
NG2/CSPG4 to overcome neuronal inflammation and structural recovery of damaged neuronal tissue.  543 
Progranulin is upregulated after spinal contusion in mice [149].  Progranulin is produced by neurons 544 
and glia and has roles in inflammation and wound repair [150, 151].  Progranulin is proteolytically 545 
processed into peptide fragments (granulins) during tissue remodelling and these display different 546 
biological activity to the native molecule.  Progranulin has trophic properties while the granulins act as 547 
inflammatory mediators and contribute to neuroinflammation, dementia and development of AD [151-548 
153].  Neuronal expression of 91 integrin, trkB, and protein tyrosine phosphatase σ (PTP , which 549 
are receptors for tenascin-C, brain derived neurotrophic factor (BDNF) and CSPGs respectively, have 550 
also been shown to significantly enhance regeneration of injured axons[154-157]. Thus with the 551 
correct expression of these cell surface receptors, growing axons can respond to appropriate guidance 552 
cues in their extracellular micro-environments by regulating their intracellular signaling pathways to 553 
modify growth cone behaviour and promote intrinsic repair [154, 156, 157]. Neuronal regeneration has 554 
been induced by transgenic integrin expression [158], lentiviral trk-B induced Erk activation [159] or by 555 
modulation of PTP expression [157]. PTPσ and the related leukocyte common antigen-related (LAR) 556 
and Nogo receptors 1 and 3 (NgR), bind the inhibitory glycosylated side chains of CSPGs and regulate 557 
synaptic structure and neuroplasticity [160, 161].   558 
 559 
 As already noted, progranulin expressed in mature neurons and microglia, has protective roles 560 
in neurogenerative disorders [162-164] and plays a central role in the regulation of neural 561 
inflammation, enhancing neuronal survival and stimulating neurite outgrowth activity. Progranulin 562 
achieves this through modulation of glycogen synthase kinase (GSK)-3Inhibition of GSK-3 has 563 
received interest as a therapeutic target in the treatment of traumatic brain injury and is 564 
neuroprotective, promoting functional recovery after intracerebral hemorrhagic stroke [165].  GSK-565 
3inhibitors rescue cognitive impairment in AD, Fragile X syndrome, Down syndrome, Parkinson’s 566 
disease and spinocerebellar ataxia type 1 [166].  Levels of phosphorylated tau protein are elevated 567 
following traumatic brain injury and may contribute to pathological structural changes in the CNS 568 
[167].  Misfolded amyloid--peptides and hyperphosphorylated tau protein accumulation is a hallmark 569 
of AD [168]. Caspase-3 regulates tau phosphorylation in AD, is mediated by the GSK-3 pathway and 570 
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involves cleavage of protein-kinase B (Akt) by Caspase-3 [168].  Progranulin thus has significant roles in 571 
the promotion of neural repair processes following traumatic brain injury and it acts in concert with 572 
CSPG4 to promote these.  The interaction of progranulin with neural PGs and neural receptors in 573 
specific regions of traumatic brain injury is mediated by GAGs attached to PGs in the traumatised area 574 
oversulphated CS isomers play a significant role in such binding interactions. This is consistent with 575 
progranulins interactive properties with the HS-PG, perlecan [169].  Oversulphated DS also displays 576 
neuritogenic activity in hippocampal neurons [170].  Novel CS/DS-GAGs identified in shark fin cartilage 577 
can bind neurotrophic factors and these also display neurite outgrowth promoting activity.  CS-578 
octasaccharides have been isolated from shark cartilage containing CS-D hexasaccharide sequences 579 
with neurite outgrowth promoting activity [171]. Novel oversulphated CS-E tetrasaccharides have also 580 
been isolated from squid cartilage [172] with neuroregulatory activity [173]. CS-E containing CS 581 
tetrasaccharides have been synthesized and demonstrated to have potent FGF-2 binding properties 582 
but their neurite outgrowth stimulatory profiles have not been determined [174] despite an earlier 583 
study which demonstrated this activity in a CS-tetrasaccharide [175]. Neurite outgrowths by 584 
hippocampal neurons are stimulated by CS-E tetrasaccharide, desulphated CS-E tetrasaccharide is 585 
inactive as is a CS-E disaccharide (Fig 7).  CS-A and CS-C inhibit neural outgrowth activity thus 586 
collectively CS isomers can both promote and inhibit neural repair. 587 
 588 
3.4 Contributions from other GAG types in neuroregulation and neural repair processes 589 
As already noted, CSPGs in glial scars prevent neurite outgrowth in-vitro and nerve regeneration in-590 
vivo[176].  Astrocytes stimulated with IL-1β do not upregulate any of their CSPG genes suggesting that 591 
these are not the only reactive glial scar proteoglycans. Rat cortical astrocytes produce more HS than 592 
CS in culture and these highly charged GAGs are more effective at stimulating nerve growth factor 593 
(NGF) signaling in PC12 cells.  Furthermore, the heparin binding domain of laminin also promotes 594 
neurite outgrowth along with NGF [177] thus HS proteoglycans also contribute to neuritogenic events. 595 
Furthermore, domain V of perlecan delays the onset of glial scarring in rat models by down-regulating 596 
neurocan and phosphacan expression and upregulating NGF activity[178]. The balance between CS and 597 
HSPG levels can therefore either inhibit or stimulate neurite outgrowth and nerve regeneration. The 598 
laminin-like LG3 fragment of perlecan is not associated with glial scarring, mice deficient in NG2/CSPG4 599 
have reduced glial scarring and are more permissive to axonal regrowth[148].  These animals have a 600 
similar phenotype to progranulin deficient mice[148]. Progranulin is neuroprotective [179] and binds to 601 
the C-terminal LG1 and LG2 repeats of perlecan domain V [180]. The C-terminal region of perlecan also 602 
binds CSPG4 [181] and has neuroprotective and pro-angiogenic properties in a rat ischemic model thus 603 
also contributes to neural repair processes [182]. Thus while CS GAGs are a major focus in this review 604 
any potential synergism or antagonistic effects with other GAG types also need to be considered in a 605 
holistic approach to better understand neural repair processes. 606 
 607 
3.5 SHH ,HS, CS, and KS interactions model tissue patterning and neural development.  608 
 Hedgehog (HH) proteins are highly conserved morphogenetic signaling molecules with 609 
fundamental roles to play in vertebrate and invertebrate embryonic development [183-186].  The HH 610 
signaling pathway plays key roles during embryonic development and remains active in adults. The 611 
GAG chains of cell surface PGs shape HH gradients and signal transduction [119, 134, 187, 188]. Three 612 
HHs have been identified in mammals, Sonic, Indian, and Desert hedgehog, these are typically 613 
expressed in the nervous system, cartilage and testis respectively. SHH is synthesized as a 45-kDa 614 
precursor protein which undergoes autocatalytic cleavage to a 20-kDa N-terminal fragment (residues 615 
24–197 in the human gene sequence) responsible for all known hedgehog biological activity. This is 616 
membrane-associated through a palmitic acid attachment at its N-terminus [189] and cholesterol at its 617 
C -terminus [190-192].  Patched (Ptc), a 12 span transmembrane protein SHH receptor acts as a 618 
negative regulator of SHH signaling.  SHH is interactive with glypican and CS GAG isomers and these are 619 
responsible for the production of SHH gradients which are a driving force during tissue morphogenesis. 620 
Surface plasmon resonance studies have demonstrated that corneal KS has interactive properties with 621 
SHH [119]. KS regulates the switch from motor neuron to oligodendrocyte generation during 622 
development of the spinal cord [134]. Glypican and CS participate in SHH mediated cell signaling [187] 623 
regulating tissue patterning and development of the neural system. SHH cell signaling is important in 624 
foetal and postnatal brain development and regulates the proliferation of early cerebral cortex 625 
progenitor and oligodendroglial lineage cells, expansion of their numbers is critical in the development 626 
of the neocortex [183, 185, 193, 194].  SHH guides axonal development during neurogenesis, cellular 627 
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responses in early brain injury  and following demyelination [195]. SHH may represent a therapeutic 628 
target to focus on in neurological disorders [196].  Co-ordinated SHH and Wnt mediated cell signaling 629 
regulates cranial nerve development [197].  SHH has roles in the differentiation of oligodendrocytes 630 
[198] and in glial neural cell communication during brain development which provides neuroprotection 631 
[186] and neuroplasticity .  Neurons diversify astrocytes in the adult brain through SHH signaling [199].  632 
SHH is a regulator of extracellular glutamate levels in epilepsy and modulates the release of 633 
gliotransmitters from cultured cerebellar astrocytes [200, 201]. 634 
  635 
3.6 CS interactions modulate neural cell behaviour. 636 
 CS is a prominent CNS GAG and occurs in a number of isomeric forms with differing degrees of 637 
sulphation and interactive properties [19, 20, 22, 202-204]. CS microarrays have proved useful in the 638 
assessment of CS-protein interactions [19, 20, 22] and has detected neurostimulatory and inhibitory CS 639 
species as well as a tumour necrosis factor  (TNF antagonist [24, 175]. Interactions of neurons with 640 
CS/DS promotes cellular survival [205]. The CS glycan chains of PGs interact with a diverse collection of 641 
proteins in the CNS to promote neural growth, proliferation, differentiation and long term survival.  642 
Some CS isoforms provide chemorepulsive nerve guidance cues which regulate axonal development 643 
and repair processes following traumatic injury. CSPGs inhibit the growth cone by interaction of CS 644 
chains with laminin, collagen and cell surface integrins.  Receptor type protein tyrosine phosphatase-645 
RPTP- also acts as a neural CS receptor [161] while RPTP- interacts with the NCAM resulting in an 646 
inhibition of neural cell adhesion and growth (Fig 8c, d).  The ecto-domain of RPTP- is enzymatically 647 
released from the cell surface by ADAMS 10 generating the soluble phosphacan which can promote 648 
neural outgrowth and repair processes. Highly charged CS isomer side chains such as CS-E on 649 
proteoglycans bind FGFs and present these to FGF receptors (FGFRs) to promote cell signaling, neural 650 
growth and differentiation (Fig 8e).  Interaction of the attractive guidance protein Semaphorin 5A with 651 
CS converts this to a repulsive guidance protein (Fig 8h).  Semaphorin 3A is a cell membrane bound and 652 
secreted short range repulsive inhibitor guidance protein which interacts with CS-E in lectican 653 
perineural net formations to inhibit nerve regrowth. This effect is mediated by interaction with 654 
neuropilin-1 and neuroplexin neural receptors (Fig 8f). Plexin acts as a signal transduction molecule 655 
along with transmembrane neuropilin co-receptors in the neuropilin-plexin receptor complex (Fig 8f).   656 
 657 
 Eph receptors and ephrins display broad spatial and temporal expression patterns throughout 658 
the nervous system [206, 207]. During early development, these interactions contribute to 659 
neurogenesis (reviewed in [208]) and differentiation [208, 209]. Eph-ephrin signaling influences the 660 
functions of Rho GTPase proteins, which in turn regulate the actin cytoskeleton influencing neuronal 661 
migration during development. Eph-ephrin signalling can generate both attractive and repulsive 662 
interactions and can positively support neurogenesis, axonal guidance and neural repair [208, 209]. 663 
EphA2 receptor tyrosine kinase is a functional cell surface receptor for the secreted glycoprotein 664 
progranulin.  Fourteen Ephrin receptors have so far been identified. Ephrin-Eph receptor cell signaling 665 
regulates cellular morphology and proliferation influencing the adhesive properties of cells during 666 
cellular migration in embryonic development, vasculogenesis and angiogenesis and has roles to play in 667 
axonal guidance, and synaptogenesis. Progranulin also promotes angiogenesis through the Ephrin 668 
receptors and upregulation of vascular endothelial growth factor (VEGF) production to modulate 669 
neuroinflammation [151, 210]. Phosphorylation of EphA2 by progranulin leads to tyrosine 670 
phosphorylation of other tyrosine kinases such as EphA4, EphB2, and EGFR through extensive cross talk 671 
(Fig 9b) among receptor tyrosine kinases [211].  Progranulin promotes the activation of the mitogen-672 
activated protein kinase (MAPK) and Akt signaling pathways.  Progranulin is secreted as a dimer 673 
containing up to 14 granulin modules per dimer which are available for protein–protein interaction. 674 
This may enable the dimer to bridge several receptors on a cell and serve as a multi-receptor signaling 675 
complex explaining the cross-talk when progranulin binds to EphA2 (Fig 9b).  676 
 677 
 The guidance of axonal development is a complex highly integrated process dependent on a 678 
myriad of inhibitory and stimulatory effector ECM proteins. Perineural net formations with hyaluronic 679 
acid (HA), tenascin-R and lectican PGs in gliotic scars are prominent stabilizing and protective 680 
structures which minimize further damage to neural tissues and protect neural cell populations in the 681 
scar from oxidative stress. Myelin-associated glycoprotein, Nogo, and the semaphorins all provide 682 
inhibitory cues over axonal development.  CS and KS interact in a sulphation-dependent manner with a 683 
number of axonal guidance proteins, including slit2, netrin1, ephrinA1, ephrinA5, and semaphorin 5B  684 
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[22]. Netrin-1 modulates axonal growth direction and speed and directs F-actin reorganization, 685 
essential for mammalian neural development.  The best characterized netrin-1 receptor, Deleted in 686 
Colorectal Cancer (DCC), is localized to growth cones, but is also observed in neuronal cell bodies [212].  687 
Netrin-1 attracts and repels distinct motor axon populations, according to the spatio-temporal 688 
expression of Netrin receptors [213] in neural tissues.  The guidance cues provided by Netrin-1 are 689 
influenced by its interactive properties with ECM PGs, a theme recapitulated by most of the axonal 690 
guidance promoter proteins.  These represent complex interplays between multiple components which 691 
regulate spatio-temporal neural growth [100, 214].  Netrin-1 can also synergize with ephrin receptors 692 
to regulate axonal formation [213]. A greater understanding of these axonal guidance cues would be 693 
insightful in therapeutic strategies aimed at producing guided nerve regeneration [215-219]. 694 
 695 
 CSPG4 promotes neural repair processes through upregulation of epidermal growth factor 696 
receptor (EGFR) expression [220, 221] and interaction with progranulin [148, 222, 223]. Progranulin is 697 
upregulated after spinal contusion [149]. CSPG4 is highly expressed by macrophages, microglial cells, 698 
tumour, perivascular and oligodendrocytes involved in cell adhesion and migration [224-228]. CSPG4 is 699 
upregulated in glioblastoma, astrocytoma and a number of other human tumours [221, 229, 230]. 700 
Activated microglial cells form synapses with neurons to participate in neural repair [224] and re-701 
organisation of the gliotic scar and improve neural outgrowth [148, 231, 232]. Following traumatic 702 
injury to the brain, the cells in the impacted area upregulate aggrecan, versican, brevican, neurocan in 703 
HA-macroaggregate perineural net structures stabilised by link protein and tenascin-R providing 704 
protection from oxidative stress and further mechanical injury.  Astrocytes seal the margins of these 705 
gliotic scars by upregulating the brain matrix proteoglycan abakan. These perineural nets inhibit nerve 706 
outgrowth. Chondroitinase ABC selectively depolymerises the CS side chains of the lectican PGs 707 
improving neural recovery in the gliotic scar [233] and improves spinal cord repair [102, 234-237].  708 
Chondroitinase C also significantly improves repair of peripheral nervous tissue but appears to have a 709 
more specific mode of action [238].  710 
 711 
 ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motifs 4) is localised 712 
in regions of the spinal cord undergoing spontaneous repair and specifically targeting of the  lectican 713 
PGs in the scar tissue [239, 240]. KSPGs are similarly up-regulated in glial scars and inhibit axonal repair 714 
[101, 113, 114, 135, 241, 242]. Mutant mice deficient in the enzyme GlcNAc6ST-1 show improved 715 
functional recovery following spinal cord injury [130]. Therapeutic use of keratanase also improves 716 
axonal repair [103]. The KSPG phosphacan is also upregulated in scar tissues where it promotes mossy 717 
fiber outgrowth and nerve regeneration [107].  Chondroitin-6-sulphate upregulated in scar tissue is 718 
reported to have nerve regenerative potential. 719 
 720 
3.7 RAGE in the brain 721 
Receptor for advanced glycation endproducts (RAGE) is a receptor which binds advanced glycation end 722 
products (AGEs) and CS in brain tissues (Fig 10).  RAGE acts as a receptor for oversulphated CS isomers 723 
such as CS-E [243, 244].  AGEs modulate amyloidogenic precursor protein (APP) processing  and Tau 724 
protein phosphorylation  regulating AD development  [245].  AGEs in glioblastoma have a modulatory 725 
role over tumour development [246].  RAGE mediates amyloid  accumulation in a mouse model of AD 726 
by regulation of β- and γ-secretase activity [247].  Targeted inhibition of RAGE reduces amyloid-β influx 727 
across the blood-brain barrier and improves cognitive deficits in mice [248].  High-mobility group box-1 728 
protein (HMGB-1) and β-amyloid oligomers promote neuronal differentiation of adult hippocampal 729 
neural progenitors via RAGE and  pathway [249]  sustaining neurogenesis counteracting the 730 
hostile AD brain microenvironment  [6].  This promotes survival of vulnerable brain cell populations 731 
[249, 250]. AGEs impair NLRP3 inflammasome-mediated innate immune responses in macrophages 732 
and modulates neuroinflammation through the  pathway [251].  733 
 734 
4. Roles for L-Fucose in Neuro Processes  735 
 736 
4.1 O- and N-linked fucosylated proteins in neural tissues 737 
 While neuronal mitochondria utilize glucose as an obligate primary energy resource in the 738 
tricarboxylic acid glycolytic pathway to generate energy neurons are also responsive to sugars other 739 
than glucose as cell regulatory agents. Positive selection pressure over at least 500 million years of 740 
vertebrate evolution has resulted in sugars which have evolved molecular recognition and information 741 
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transfer properties equipping them as cellular mediators serving as critical determinants of protein 742 
folding, trafficking, and stability .  Glycans are abundant in the brain and are involved in various neural 743 
functions including learning and memory, brain development, and spinal cord injury [102, 252-254].  744 
The precise molecular mechanisms whereby glycans influence these processes is not well understood 745 
but it is clear that synaptic transfer of information between neurons occurs through glycoprotein 746 
mediated interactions.  L-fucose exists as a terminal residue on N- or O-linked glycoproteins attached 747 
to the C-3 and C-6 position of N-acetylglucosamine or the C-2 position of galactose (Fig 4).   The fucose 748 
α1-2 galactose (Fuc α1-2Gal) linkage has been implicated in cognitive processes such as learning and 749 
memory. Non-invasive two dimensional magnetic resonance spectroscopy (2D MRS) has identified six 750 
Fuc α1-2 Gal sugars in brain tissue. 2D MRS offers an unprecedented insight into the molecular 751 
mechanisms by which fucosylated sugars contribute to neuronal processes and how they alter during 752 
development, ageing and disease [29]. Fucose is an unusual sugar in that it exists as a 6-deoxy L-753 
galactopyranose configuration and is a prominent functional component of neural tissues such as 754 
synaptic membranes [29].  Addition of 2-deoxy D-galactose, an L-fucose analog to hippocampal 755 
neuronal cultures potently inhibits neural outgrowth activity whereas 3-deoxy D-galactose is inactive, 756 
moreover addition of D-galactose to 2-deoxy-D-galactose treated cultures results in the functional 757 
recovery of normal neuron growth characteristics. Fuc α 1-2 Gal is a non-reducing terminal component 758 
of many glycans [29] and is implicated in neurite outgrowth, synaptogenesis, neuronal development, 759 
learning, and memory [27, 28, 255, 256].  Treatment of animals with 2-deoxy-D-galactose, disrupts the 760 
formation of Fuc α 1-2Gal linkages, and causes reversible amnesia [257] interfering with the 761 
maintenance of long-term potentiation in an electrophysiological model of learning and memory [258].  762 
Furthermore loss of 1, 6-fucosyl transferase activity also decreases hippocampal long term potentiation 763 
[259].  764 
 765 
  -fucose is a terminal or core monosaccharide on N-and O-linked glycan chains on many 766 
glycoproteins  (Fig 4d, Fig 5a-g).  It also occurs as a capping structure along with sialic acid on the KS-I 767 
and KS-II chains of PGs (Fig 4a-c) and in terminal sLeX motifs in glycoproteins (Fig 4f, Fig 5b, Fig 6f-h).  768 
KS is heavily substituted with fucose and sialic acid in ALS. The prominent terminal locations of L-fucose 769 
points to its role as a molecular recognition site for interacting proteins. Fucose occurs as a terminal 770 
sugar linked to a penultimate galactose residue in glycoconjugates or to core GalNAc residues in N-771 
glycans (Fig 5b,f).  Fucose can also be directly attached to serine or threonine residues by fucosyl 772 
transferases in O-linked glycans and can act as an acceptor molecule for the attachment of further 773 
saccharides to form small oligosaccharide side chains (Fig 4e). 774 
 775 
4.1.1 L-Fucose as a functional component of blood group substances and Immunoglobulins 776 
 Fucose also occurs as terminal Fuc 1-2 Gal terminal saccharides in small glycolipids attached 777 
to red blood cells identifying the A, B, O blood group antigens (Fig 6a).  Over 95% of circulatory human 778 
IgG antibodies also contain a fucose (core-fucose) residue attached to the first GalNAc in the 779 
glycosylation site of their Fc region.  The majority of other plasma proteins are not substituted with 780 
fucose in this manner.  Fucosylation dramatically reduces IgG binding to FcγRIIIA, an activating Fc 781 
receptor specific for IgG Fc region expressed by immune human natural killer (HNK) cells and 782 
macrophages [260-262]. FcγRIIIA initiates antibody dependent cellular cytotoxicity (ADCC) by HNK cells 783 
and phagocytosis of antigens by macrophages. This core fucose attenuates potentially harmful ADCC 784 
activity. Conversely, ADCC induced by non-fucosylated IgG improves the efficacy of therapeutic 785 
anticancer antibodies.  IgG lacking the core-fucose is over 100 times more effective in initiating ADCC 786 
than the fucosylated version (Fig 6b-h).  787 
 788 
4.1.2  Synapsin and Synaptophysin  789 
 The synapsins are fucosylated proteins [256] which regulate the release of synaptic vesicles to 790 
coordinate release of neurotransmitters within the synaptic vesicles at the synaptic gap [263].  They do 791 
so by tethering the vesicles to cytoskeletal components to prevent the diffusion of vesicles to the 792 
synaptic membrane preventing the un-coordinated release of neurotransmitters at the synaptic gap 793 
[264].  During the transmission of an action potential down the neuron from the cell body the 794 
synapsins are phosphorylated by cAMP dependent protein kinase (PKA).  This releases the synaptic 795 
vesicles to the pre-synaptic membrane [265] which depolarizes in response to the action potential 796 
allowing the synaptic vesicle to fuse with the synaptic membrane and release the enclosed 797 
neurotransmitters into the synaptic gap and these are transported across to the post synaptic 798 
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membrane of a communicating neuron [266].  This results in the transmission of neural signals along 799 
the neural network.  There are three synapsin proteins and each occur as two isoforms.  Synapsin 1a is 800 
implicated in bipolar disorder and schizophrenia [267]. The synapsin Ia/Ib isoforms are the most highly 801 
expressed hippocampal pre-synaptic vesicle associated phosphoproteins and are implicated in thought 802 
formation and cognitive learning [268-270].  Synapsin is a major neuronal fucosylated glycoprotein 803 
[256, 271, 272].  The synapsin family consists of 3 major isoforms encoded by 3 genes  SYN1, SYN2, 804 
SYN3.  Each gene occurs as two alternatively spliced forms leading to a total of six isoforms. Mice 805 
lacking synapsin I, II, III are prone to seizures and display learning difficulties and in humans is 806 
associated with bipolar disorder and Schizophrenia[34, 267]. 807 
 808 
4.1.3 Fucosylated Glycoproteins and Proteoglycans 809 
 Fucosylated glycoproteins and PGs have prominent roles in many physiological and 810 
pathological processes including leucocyte adhesion, host-microbe interactions, neuronal development 811 
and neural protection[273-275].  Fucosylated glycolipids on erythrocytes form the ABO blood group 812 
antigens[276].  However, aberrantly fucosylated glycoconjugates are also found in cancer, 813 
inflammation and neoplastic processes [276-279].  The fucosylated sialyl Lewis-X, and sialyl Lewis-Y 814 
antigens are prominently upregulated in some cancers and associated with tumour progression.  815 
Deficient levels of fucose occur in impaired leucocyte interactions with the vascular epithelium in 816 
immunodeficiency. Leukocyte adhesion deficiency II (LAD II) is a rare congenital disease caused by a 817 
defect in fucosylation of glycoconjugates such as P-selectin glycoprotein ligand-1 (PSGL-1) (Fig 5a) 818 
which normally facilitate leucocyte binding to the selectins on the epithelium during inflammation 819 
[280].  This interaction facilitates leucocyte rolling and their extravasation through blood vessels to 820 
tissue sites to combat infection.  Leukocyte adhesion deficiency type II (LAD II)-patients show severe 821 
mental and growth retardation indicating an additional essential role for fucose in brain growth and 822 
development [281].  The P-selectin PSGL-1 ligand is a dimeric mucin-like 120-kDa glycoprotein located 823 
on leukocyte surfaces that binds to P-, E- and L-selectin and promotes leucocyte adhesion to the 824 
endothelium facilitating leucocyte rolling during inflammation.  PGSL-1 is heavily fucosylated as part of 825 
the branched Lewis X antigen O- 3Galß14[Fuca13]GlcNAcß1R)[125] 826 
(Fig 5a). High affinity cell adhesion interactions also require the presence of three tyrosine sulfate 827 
residues located near the Lewis-X antigen structure at the N-terminus of PSGL-1 [125, 282, 283]. 828 
 829 
4.1.4 Functional role of L-Fucose in Notch Signaling 830 
 O-fucosylation is essential for the functional properties of Notch [124, 284, 285], a 831 
transmembrane receptor that co-ordinates a number of cell-fate decisions in neural development and 832 
in neuron-glial cell interactions which determine neuritogenesis, neuronal migration and 833 
differentiation[286] (Fig 5g). Fucose knockout causes developmental defects in mice and abnormal 834 
vasculogenisis, somitogenisis and neurogenesis [124], Notch is an important mediator in all of these 835 
processes. Notch-1 is a member of a family of transmembrane glycoprotein receptors which contains a 836 
large number of extracellular epidermal growth factor repeats.  These are heavily substituted with 837 
fucose providing the extracellular Notch domain with important interactive properties (Fig 5g).  Ligand 838 
binding to the extracellular domain of Notch-1 by Delta, Jagged or Serrate ligands induces proteolytic 839 
cleavage of Notch and the cleaved intracellular domain enters the nucleus to modify gene functions. 840 
Upon ligand binding with Notch, ADAM 10 cleaves the extracellular domain and this continues to 841 
interact with the ligand in solution.  The intracellular portion of Notch is then cleaved by -secretase 842 
and it is transported to the nucleus where it regulates gene expression through the transcription factor 843 
CSL, an acronym for CBF-1/RBPJ (recombining binding protein suppressor of hairless). CSL acts as a co-844 
repressor negatively regulating Notch signaling to control cell fate decisions[121, 287] in 845 
developmental contexts.  Notch is widely expressed in many cell types and has fundamental roles in 846 
development.  847 
 848 
 Fucose occurs on structurally diverse N- and O-linked glycans through the action of over a 849 
dozen fucosyl biosynthetic enzymes.  Fucosyl transferase 1 (FUT1) and FUT2 attach fucose to galactose 850 
in Fuc  1-2 Gal containing glycans.  FUT3 attaches Fuc via  1-3 and 1-4 linkages to Gal and GlcNAc 851 
residues in glycan chains. FUT4-7 form exclusively  1-3 linked fucose residues in glycans.  FUT8 and 852 
FUT9 generate Fuc 1-6 GlcNAc linkages, FUT8  attaches these to core asparagine residues in N-glycans 853 
whereas FUT9 attaches these to the GlcNAc units of polylactosamine chains.  FUT10 and FUT11 are 854 
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putative fucosyltransferases catalyzing the generation of  1-3 linked Fuc in glycans.  POFUT1 and 855 
POFUT2 are O-fucosyltransferases which attach Fuc directly to serine and threonine residues in the 856 
modular EGF and thrombospondin repeats of glycoproteins. 857 
 858 
 Although a relatively minor sugar, its strategic positioning on key functional glycoproteins 859 
points to fucose having a significant role to play in neural pathobiology.  As already indicated O-860 
fucosylation is essential for the activity of Notch (Fig 5g) and has significant roles to play in leucocyte 861 
PSGL-1 P-selectin mediated interactions (Fig 5a) with the endothelium in neuro-inflammation [286].  862 
CD-34 is heavily substituted with both N- and O- linked fucosylated oligosaccharides in microvascular 863 
progenitor cells (Fig 5e). The mode of action of L-Fuc in Notch has been suggested to be due to 864 
induction of conformational changes in the epidermal growth factor (EGF) repeat domains or in the 865 
Notch ligands.  Notch signaling is essential for the maintenance of neural progenitors and regulates 866 
cell-fate decisions in neuronal and glial cells to modulate neuronal differentiation and migration [288, 867 
289]. Deletion of POFUT1 is embryonic lethal causing developmental defects in vasculogenesis, 868 
somitogenesis and neurogenesis similar to those obtained when Notch receptors are deleted.  This 869 
reinforces the importance of L-Fuc as a mediator in combination with Notch in neuronal development. 870 
 871 
4.1.5 Roles for L-Fucose in CD-34. 872 
 Another cell surface protein with cell adhesion and cell regulatory properties in the CNS/PNS 873 
is CD-34 (Fig 5e).  CD34 is a heavily fucosylated type I transmembrane sialoprotein, that can be 874 
phosphorylated by a number of kinases including PKC and Tyrosine kinase. The CD-34 proteins are a 875 
family of sialomucin transmembrane adhesion proteins.  CD-34 is expressed in early haematopoietic 876 
and vascular tissues and lymph node epithelium. CD-34 interacts with L-selectin expressed by T cells in 877 
the lymph node epithelium.  Podocalyxin and endoglycan are related to CD-34 and also facilitate cell 878 
attachment and cell migration during microvessel development in neural tissues [126].  Terminal 879 
fucosylation of these PGs confer unique functional properties in a variety of biological settings. Fucose 880 
is an essential component of the carbohydrate ligands for the selectin family of cell adhesion receptors 881 
[290, 291]. E-, P-, and L-selectin are C-type lectin proteins expressed by platelets (P-selectin), 882 
endothelial cells (E- and P-selectin), and leukocytes (L-selectin). Selectins bind to oligosaccharides 883 
decorating specific cell surface and secreted proteins expressed by leukocytes (E- and P-selectin 884 
ligands) and high endothelial venules (L-selectin ligands). Interaction between selectins and their 885 
ligands enable the rolling of leukocytes on the endothelium, and is an essential requirement for 886 
leukocyte extravasation. The carbohydrate selectin ligands are fucosylated structures related to the 887 
sialyl Lewis-X antigen, an 1,3-fucosylated glycan structure also known as stage-specific embryonic 888 
antigen-1 (SSEA-1) and CD15 expressed during early embryogenesis [292].  889 
4.1.6 L-Fucose as a component of Lewis-X-Antigen 890 
 Lewisx  epitopes are present in multiple areas of the developmental embryonic brain[293-891 
296], controlled by FUT 9 expression, an enzyme which is regulated by the transcription factor Pax 6 892 
[297]. The functional role of Lewisx in the developing brain has yet to be determined, but its dynamic 893 
expression patterns during embryogenesis suggests it may have roles in aspects of molecular 894 
recognition which support the assembly of neural structures [273, 298].  The Lewisx  epitope, an  1,3-895 
fucosylated glycan also known as the stage-specific embryonic antigen-1  (SSEA-1) and CD15, is 896 
expressed during early embryogenesis [292]. Exposure of pre-implantation mouse embryos at the 897 
morula developmental stage to Lewisx oligosaccharides causes decompaction apparently through 898 
disruptive multimeric interactions affecting cell-cell adhesion in early embryos [299, 300]. 899 
Oligosaccharides containing L-fucose form part of a recognition signal in sperm–egg attachment in 900 
mammals [301].  At the endometrial surface, adaptations are also required to accommodate the 901 
implanting embryo [302, 303].  These adaptations at the materno-fetal boundary are highly species-902 
specific. Fucose containing carbohydrate structures in the embryonic–maternal interface have 903 
important molecular recognition roles to play which define the maternofetal glyco-code.  Localization 904 
of fucose oligosaccharides at a surface or interface is important in predicting functional roles in cell 905 
recognition. Each mammalian species has its own characteristic materno-fetal glyco-code.  This 906 
glycotype permits interbreeding between compatible species like the horse and donkey which have 907 
almost identical patterns of placental glycosylation, whereas the camel has a totally different placental 908 
glycosylation signature and cannot interbreed with either the horse or donkey [304]. Specific 909 
fucosylated glycoconjugates vary in abundance during the receptive and non-receptive phases of 910 
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implantation [305] and are altered in the infertile endometrium [306]. By analogy with selectin 911 
mediated intercellular adhesive interactions during extravasation of leucocytes in the innate immune 912 
response a similar process may occur at implantation between endometrial sialyl Lewisx and 913 
trophectodermal selectins [307-309]. Overexpression of FUT 7 in a mouse implantation model 914 
promotes embryo adhesion and implantation [310, 311]. Thus fucose oligosaccharides may serve 915 
molecular recognition roles both in the fertilization and implantation stages of reproduction. 916 
 917 
Defucosylation of the EGF domain from urokinase-type plasminogen activator abolishes its mitogenic 918 
activity despite having no effect on its binding properties at the cell surface , thus O-fucosylation can 919 
modulate ligand-receptor interactions necessary for productive signal transduction outcomes. O-920 
fucose residues are also present on EGF domains of the mammalian Notch receptors, a family of 921 
transmembrane cell-fate determining signaling proteins during somite formation, neurogenesis, 922 
angiogenesis, and lymphoid development. Ligand-induced Notch signaling events are impaired in a 923 
fucose-deficient cell line but can be restored by correction of the fucosylation defect, indicating that O-924 
fucosylation of Notch affects its interactions with ligands and is in line with functional roles for L-fucose 925 
in molecular recognition [312, 313].  Such O-fucosylation effects are not limited to EGF domains, as 926 
glucose-extended fucose modifications (Glc-Fuc-O -Ser/Thr) have been demonstrated in three 927 
thrombospondin type 1 repeats on thrombospondin-1 [78] and it remains to be determined if the 928 
activity of additional protein modules can also be  modified by O-fucosylation. Fucosylated glycans 929 
impact on the pathogenesis of several human diseases. Expression of A and B blood group antigens (Fig 930 
8a) is lost in many tumours accompanied by increases in H and Lewis-Y expression associated with poor 931 
clinical prognosis [314, 315]. Up-regulation of sialyl Lewis-X  and sialyl Lewis-a  occurs in many cancers 932 
associated with advanced tumor grade and poor prognosis. Increased expression of fucosylated serum 933 
immunoglobulins (Fig 6f-h) is evident in juvenile and adult rheumatoid arthritis [260, 261] its 934 
contribution to the pathogenesis of inflammatory arthritis is not known or whether this is a secondary 935 
effect due to an upregulation in fucosylation driven by an autoimmune response. Elevated fucosylation 936 
of mucins has also been observed in cystic fibrosis, accompanied by a decrease in sialylation [278]. 937 
Fucosylation impacts on leukocyte recruitment, selectin-selectin ligand interactions and the 938 
development of numerous pathological processes, including atherosclerosis, reperfusion injury 939 
following ischemic events, inflammatory skin diseases, and asthma [316].  A reduction in the density of 940 
cell surface fucosylated glycans in patients with LAD II (also known as congenital disorder of 941 
glycosylation) [280] results in  recurrent infections due to defective selectin ligand biosynthesis and an 942 
impairment in the innate immune response. Mental retardation and skeletal abnormalities are also 943 
prominent features in LAD II, but it is not known if these are due directly to fucose-dependent 944 
processes, such as O-fucosylation of Notch receptors or are due to Lewis-X mediated interactions in the 945 
embryonic brain. 946 
 947 
4.2 Fucosylated Chondroitin Sulphate as a Therapeutic Agent 948 
 Investigations over the last 25 years [317-319] on fucosyated CS (Fuc-CS) isolated from the 949 
holothurian echinoderm marine sea cucumber (Holothuroidea class) has identified a family of 950 
molecules with great therapeutic potential in a number of physiological processes (Fig 4h).  The Fuc-951 
CSs consist of a core structure consisting of CS-E and CS-A disaccharides with CS-A constituting 10-50% 952 
of the disaccharides.  Sulphated fucose side chains are attached through O-3 to GlcA of the core 953 
structure. These fucose residues can be monosulphated or disulphated at the 2,4 or 3,4 positions (Fig 954 
4g, h), side chains and disulphated GlcA in the core structure have also been detected adding to the 955 
structural complexity and charge density of the Fuc-CSs.  Native Fuc-CS preparations have been 956 
isolated up to 64 kDa in size and for some therapeutic applications these have been depolymerized to 957 
smaller 3-12 kDa forms.  The branched sulphated fucose side chains are important features of the Fuc 958 
CSs [320, 321].  Synthetic branched 2,4-di-O-sulphated fucosylated CS glycoclusters have been 959 
prepared in order to reproduce this structural feature, these display anti-coagulant properties and 960 
specific inhibition of intrinsic coagulation pathways [322].  Furthermore, the activated partial 961 
thromboplastin time (APTT), prothrombin time (PT) and thrombin times (TT) of these polymers can be 962 
fine-tuned for specific therapeutic applications [322].  The structural features of the Fuc-CSs have been 963 
investigated using high-resolution Fourier transform ion cyclotron resonance mass spectrometry [323] 964 
and to chemical and NMR spectroscopic structural  investigations [324, 325].  In NMR and molecular 965 
dynamic simulations, the Fuc-CS repeat unit adopted a similar conformation to the Lewis-X blood 966 
group determinant [326, 327].  This structure accommodates the localization of several sulphate 967 
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groups in close proximity to one another and these form large negative patches which are distributed 968 
along the helical CS backbone of Fuc-CS [326, 327]. Native Fuc-CS preparations display anti-coagulant 969 
[323, 328-331] anti-angiogenic [329], anti-inflammatory, blood lipid lowering properties [323, 328-970 
333], and stimulate haemostasis [334], promote neurite outgrowth [335], anti-cancer [336] and potent 971 
HIV-1 gp 120 protein binding properties which inhibit HIV replication by preventing viral entry into cells 972 
[337].  While neurite outgrowth promoting properties have been noted for native Fuc-CS preparations, 973 
a synthetic Fucose-CS trisaccharide (Fig 4j) has been shown to be more potent than CS-E 974 
tetrasaccharides (Fig 7) for the outgrowth of DRG hippocampal neurons in monolayer culture.  The 975 
molecular recognition properties of specific glycan structures can therefore be employed in 976 
therapeutic interactions of physiological importance and undoubtedly when further information 977 
becomes available on these structures will also be employed in improved applications in repair biology. 978 
 979 
5. Conclusions 980 
Fucose, CS and KS have evolved properties of molecular recognition and information transfer which 981 
equips the proteoglycans and glycoproteins they are attached to with properties as cellular mediators 982 
controlling cellular behaviour in a number of physiological processes and in neural development and 983 
repair.  A greater understanding of this evolved glycocode and how it regulates cells may allow a 984 
greater understanding of physiological and repair processes and how these might be manipulated in 985 
order to improve therapeutic interventions developed in response to altered glycodynamics in neural 986 
disorders.  These are expected to improve repair responses in cognitively impaired brain tissues. 987 
  988 
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Legends to Figures 989 
 990 
Figure 1.  991 
Morphological features of cultured neurons. Fluorescent images of cultured neural iPSCs (a) and 992 
neuroblastoma cells (b) and IPSCs stimulated with nerve growth factor (c).  In (a) cell nuclei were 993 
stained with Hoechst 33258 DNA stain, axons with anti-tubulin Alexa 488 and dendrites and synapses 994 
with anti-F actin phalloidin Alexa 568. In (b) cultured mouse neuroblastoma cells were stimulated with 995 
retinoic acid to induce differentiation.  Nuclei (i.e. DNA) are stained yellow; microtubules (anti-tubulin 996 
antibody) are cyan; f-actin (fluorescent phalloidin) is purple. The image was pseudo- coloured, 997 
individual channels were initially recorded with the regular red/green/blue fluorophors (i.e. Alexa 488 998 
and 568 and DAPI) then pseudo coloured as shown. Images a, b, c supplied courtesy of Torsten 999 
Wittmann, PhD, Dept of Cell and Tissue Biology, University of California, San Francisco, USA.  Indirect 1000 
fluorescent immunolocalisation of paraformaldehyde fixed rat hippocampal neurons with anti-1001 
synapsin-1/2 (red, Alexa 488) raised to a synthetic peptide corresponding to amino acids 2 to 28 from 1002 
rat Synapsin-1 (UniProt Id: P09951)[cat # 106-006] and mouse anti-microtubule associated protein 1003 
(MAP-2, green, FITC) [cat# 188-011], nuclei stained with DAPI (blue) (d).  Image d supplied courtesy of 1004 
Synaptic Systems. 1005 
 1006 
Figure 2.   1007 
Neural structural organisation and synaptic neurotransmitter transmission.  Artistic rendition of a 1008 
synapse with progressive stages of transmission of neurotransmitters across the synaptic gap to a 1009 
communicating neuron (a-c).  Diagrammatic representation of SV2A proteoglycan intercalated in the 1010 
plasma membrane of a synaptic vesicle and the Ca2+ /neurotransmitter (GABA) smart gel complex 1011 
formed by interaction with the KS side chains of SV2A which forms a neurotransmitter transport 1012 
delivery system (d). Pseudo coloured TEM of a synapse (X 50,000) courtesy Science PhotoLibrary.  1013 
Michondria (purple), synaptic vesicles (red), synaptic gap (pink) (e). Diagrammatic depiction of a 1014 
synaptic bouton with 1. microtubular transport system which transports the  neurotransmitters 1015 
generated in the neural cell body.  2. mitochondria and 3. synaptic vesicle accumulation in the synaptic 1016 
terminal and 4.the post synaptic neurotransmitter receptors and voltage gated ion-channels on a 1017 
communicating neuron which deliver neurotransmitters such as GABA (as shown) (f).   Higher power 1018 
view of the boxed area in (f) showing details of the depolarisation of the synaptic membrane and 1019 
merging of synaptic vesicle plasma membrane and delivery of Ca2+ and neurotransmitters across the 1020 
synaptic cleft to neurotransmitter receptors and voltage gated ion channels in a communicating 1021 
neuron (g).  Details of synaptic vesicles adjacent to the synaptic membrane of the synaptic cleft viewed 1022 
by TEM (h).  Plates a-c from  Shutterstock.  Plate d modified from [338] and f-h modified from Becker, 1023 
W., Hardin, J., Bertoni, G., Kleinsmith, L. (2012). Becker's World of the Cell (8th ed.). Boston, MA: 1024 
Benjamin Cummings. Source: http://www.mun.ca/biology/desmid/brian/BIOL2060/BIOL2060-1025 
13/13_16.jpg   A neuron and surrounding glial cells. (i)  H & E stained section of neural tissue depicting 1026 
a central large neuron body with multiple prominent dendritic processes surrounded by numerous 1027 
small glial cells.  Image obtained from Pinterest.  Cartoon depicting the co-ordinated interplay between 1028 
neurons and blood vessels mediated by astrocytic interconnections (j).  1029 
 1030 
Figure 3.   1031 
Immunolocalisation of aggrecan in perineural nets using MAb 1-B-5 following chondroitinase ABC 1032 
digestion of rat brain (a), rat dorsal root ganglion (b) or in isolated neurons (c, d).  Images courtesy of 1033 
Caterson archive, BioImaging Unit, University of Cardiff. 1034 
 1035 
Figure 4. 1036 
Fucosylation of KS-I (a) and KS-II from the KS rich region of aggrecan (b) and KS-II chains located within 1037 
the CS2 region of the aggrecan core protein (c) which are detected by MAb 3D12H7. Fucose modified 1038 
glycan structures. The structural diversity of the L- fucose containing glycan chains of O-linked glycans 1039 
of the mucin family (d-f), small glycan chains where L-fucose is linked directly to O-serine residues of 1040 
the glycoprotein or proteoglycan core protein and which acts as an acceptor molecule for subsequent 1041 
additions of additional saccharides (e) and the 6-sulphated Lewis-X epitope which has a widespread 1042 
distribution in glycoproteins (f).Fucosylated chondroitin sulphates (Fuc-CS) of therapeutic potential (g). 1043 
Representative structure of a native Fuc-CS [327] isolated from sea cucumber (g) The structure shown 1044 
is that specified for a Fuc-CS displaying interactive properties with P-and L-selectin which prevented 1045 
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selectin mediated extravasation of neutrophils in inflammation.  The fucose side chains of Fuc-CS 1046 
display some structural variation as shown in the proportion of mono- and disulphated fucose side 1047 
chains (h).  Structure of the CS-A and CS-E disaccharide core structures (i).  The CS-A content of the 1048 
core varies between 10%-50%. Structure of a fucosyl-CS trisaccharide (j) which displays potent neurite 1049 
outgrowth promoting activity[335].    1050 
 1051 
Figure 5.   1052 
O-fucosylated PSGL-1, CD-34 and Notch-1.  Schematic depiction of the structural organization of PSGL-1053 
1 of leucocytes which facilitates binding to P-selectin in the endothelium (a).  PSGL-1 is heavily 1054 
substituted with O- linked L-fucose oligosaccharides containing the sialyl Lewis X epitope (b). A 1055 
terminal sialyl LeX epitope is associated with sulphated tyrosine residues which are important for the 1056 
interactive properties of PSGL-1 with P-selectin. Fucose modifications on branched glycan structures in 1057 
PSGL-1 (b). The structural diversity of the L-fucose containing glycan chains in N-linked glycans  1058 
displaying tri-antennary, tetra-antennary, high mannose, bi antennary glycan chains and those bearing 1059 
the N-linked 6-sulphated Lewis-X epitope. 1060 
O- and N-fucosylation of CD-34. Diagrammatic representation of the CD-34 cell surface receptor that is 1061 
widely expressed by a number of microvascular cells in brain development (c-f). N- and O- linked 6-1062 
sulphated Lewis-X motifs are prominent interactive components of CD-34 (c, e, f) these are shown 1063 
distributed along the core protein of a model of the transmembrane  CD-34 molecule (d).The key 1064 
contribution of O-fucosylation to Notch functional organization (g).  Structural representation of the 1065 
Notch-1 receptor modular structural organization and the glycosylation of its epidermal growth factor 1066 
(EGF) repeat units which conveys its interactive properties with a number of ligands (h).  The EGF 1067 
repeats are particularly heavily substituted with L-fucose containing glycans as shown, while the other 1068 
glycosylations have a regulatory role to play over the interactive properties mediated by  L-fucose 1069 
glycans.   Blood vessels can be visualized in human brain tissues using CD-34 immunolocalisation, 5 1070 
week post conception spinal tissue (i). Abbreviations  HB , hind brain; OT, otic nerve; SC, spinal cord. 1071 
Image obtained by Open Access from llgård K, Dziegielewska KM, Holst CB, Habgood MD, Saunders NR. 1072 
Brain barriers and functional interfaces with sequential appearance of ABC efflux transporters during 1073 
human development. Sci Rep. 2017 ;7(1):11603.  1074 
 1075 
Figure 6.  1076 
Fucosylated blood group antigens and immunoglobulins.  Fucose containing glycan chains attached to 1077 
red blood cells which  identify the A, B, O blood types (a).   Glycan chains attached to serum 1078 
immunoglobulins (b) which determine ADCC toxicity which some IgGs elicit (c-e)  and an inflammatory 1079 
response (f-h) 1080 
 1081 
Figure 7 .  1082 
Neurostimulation by glycans and glycosaminoglycans.  The stimulatory effect of CS-E saccharides on 1083 
cultured hippocampal neurons.  Immuno-fluorescent localisation of neurons cultured ± CS-E 1084 
saccharides using anti-tau FITC antibodies (a-d). Control (a), CS-E disaccharide (b), unsulphated CS-E 1085 
tetrasaccharide (c), d. CS-E tetrasaccharide (d),   Scale bars =45 m.  The minimum size of CS-E required 1086 
for neuronal stimulation was a CS-E tetrasaccharide, the non sulphated CS-E tetra-saccharide and CS-E 1087 
disaccharide were both non-stimulatory. This contrasts with CS-A and CS-C which inhibit neural 1088 
outgrowth. L-fucose and related sugars also have stimulatory properties of on cultured hippocampal 1089 
neurons (e-h).  L-fucose (6-deoxy L-galactose), D-galactose and deoxy D-galactose saccharides all 1090 
influence the morphology of cultured hippocampal neurons.  Immunofluorescent detection of dendrite 1091 
outgrowth from cultured hippocampal neurons using FITC labeled anti-tau antibodies. Control, L-1092 
fucose (e), 2-deoxy L-galactose (f);  2-deoxy L-galactose + D-galactose (g);  3 deoxy L-galactose (h).   2-1093 
deoxy D-galactose has an inhibitory effect on dendrite outgrowths.  The structures of these sugars are 1094 
shown in (i)-(m).  The structure of an L-Fuc analogue, 6 alkynyl Fuc which is used in the labeling and 1095 
tracking of O-Fucosylation in glycoproteins is also shown (n) [79]. Images a-h reprinted (adapted) with 1096 
permission from  from Murrey HE, Hsieh-Wilson LC. The chemical neurobiology of carbohydrates. 1097 
Chem Rev. 2008 ;108(5):1708-31,and Tulley SE, Mabon CI, Gama CI, Tsai SM, Liu X and Hsieh-Wilson LC.  1098 
J am Chem Soc  2004; 126, 7736-7737 copyright (2004 and 2008) American Chemical Society.  1099 
 1100 
Figure 8.  1101 
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Diagrammatic depiction of interactive structures on the surface of neurons and the contributions of CS-1102 
proteoglycans to neural growth arising from interactions with cell surface integrins, laminins and 1103 
pericellular collagen and fibronectin fibres and hyaluronan(a) and RPTP- (b)which acts as a CS-1104 
receptor (1).  Neural outgrowth arising from the interaction of RPTP- with NCAM (neural cell adhesion 1105 
molecule) (c,d) (2).  Cellular proliferative and cell survival effects stimulated by delivery of fibroblast 1106 
growth factors to their receptors (FGFR)(e) (3).  Chemorepulsive cues generated by interaction of CS-1107 
proteoglycans in perineural net formations with semaphorin 3A which is normally an attractive 1108 
guidance cue.   This inhibitory signal is generated by interactions of Sem3A with neuropilin-1 and 1109 
neuroplexin (f,g).  Semaphorin 5A also interacts with cell surface CS-proteoglycans generating a signal 1110 
which inhibits nerve outgrowth (h).  Figure modified from L Djerbal, H Lortat-Jacob, JCF Kwok 1111 
Chondroitin sulfates and their binding molecules in the central nervous system Glycoconj 1112 
J. 2017; 34(3): 363–37. Open Access. 1113 
 1114 
  1115 
Figure 9.  1116 
Diagrammatic illustration of the interaction of progranulin dimer with CSPG4 (a) and Eph A2 showing 1117 
the resulting phosphorylation of Eph A2 and cross-talk with adjacent receptors leading to their 1118 
activation. Figure available under a Creative Commons License (Attribution–Noncommercial–Share 1119 
Alike 3.0 Unported license),  http://creativecommons.org/licenses/by-nc-sa/3.0/). Bateman A. 1120 
Progranulin and the receptor tyrosine kinase EphA2, partners in crime? J Cell Biol. 2016;215(5):603-1121 
605.  1122 
 1123 
Figure 10.   1124 
Schematic depiction of the structural organization of transmembrane RAGE showing its extracellular, 1125 
transmembrane and cytoplasmic portions and the glycan interaction region which acts as a receptor 1126 
for AGEs and highly charged CS isomers such as CS-E.  Diagram reproduced from Hegab Z, Gibbons S, 1127 
Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J 1128 
Cardiol. 2012;4(4):90-102. Under Open Access creative commons attribution Non Commercial (CC BY-1129 
NC4.0) licence with permission of Bashideng Publishing Group, CA, USA. 1130 
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